Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ: ATAI )

2.090 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
27 28 Next >
The "Rags-To-Riches" Portfolio Update: Week Ending January 27
The Rags-to-Riches Portfolio tracks the performance of 14 cannabis, psychedelic and plant-based food stocks constituent . Here, performances last week and year-to-date. 
Via Talk Markets
Top 3 Psychedelic Storylines To Watch In 2023
This article by James Hallifax was originally published on Microdose and appears here with permission. 
Via Benzinga
Largest Psychedelic Stocks +1.2% This Week; Now +16.1% YTD
We track the 6 largest psychedelic stocks that research the treatment of mental illnesses based on the use of one or more psychedelic substances - weekly and YTD results. 
Via Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
Via Benzinga
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks
Via Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 11, 2023
Via Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 10, 2023
Via Benzinga
What 4 Analyst Ratings Have To Say About ATAI Life Sciences
Via Benzinga
ATAI Life Sciences, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Atai Life Sciences Investor Christian Angermayer Addresses Recent Trial Results And Pipeline Outlook
In our latest Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer. 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 23, 2023
Via Benzinga
"Rags-To-Riches" Portfolio Update: Week Ending January 20, 2023
My new portfolio of 14 cannabis, psychedelic and plant-based food stocks were cumulatively pretty awful in 2022, thus could well offer high returns in 2023. 
Via Talk Markets
Largest Psychedelic Stocks +3% This Week; Now +15% YTD
Our Psychedelic Drug Stocks Index tracks the six largest psychedelic stocks, by market capitalization, that research the treatment of mental illnesses based on the use of one or more of 10 different... 
Via Talk Markets
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. 
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 9, 2023
Via Benzinga
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
From atai Life Sciences
Via GlobeNewswire
My "Rags-To-Riches" Portfolio For 2023: An Introduction
The performance of cannabis, psychedelic and plant-based food stocks in 2022 were just horrible; is there any way to go but up? 
Via Talk Markets
atai Life Sciences' Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.